38,877 Shares in Pfizer Inc. (NYSE:PFE) Acquired by Lmcg Investments LLC

Lmcg Investments LLC purchased a new position in shares of Pfizer Inc. (NYSE:PFEGet Rating) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 38,877 shares of the biopharmaceutical company’s stock, valued at approximately $2,012,000.

Other large investors have also recently made changes to their positions in the company. State Street Corp boosted its stake in Pfizer by 1.8% during the fourth quarter. State Street Corp now owns 284,816,832 shares of the biopharmaceutical company’s stock worth $16,818,434,000 after buying an additional 5,013,651 shares during the last quarter. Geode Capital Management LLC boosted its stake in Pfizer by 1.5% during the fourth quarter. Geode Capital Management LLC now owns 101,065,073 shares of the biopharmaceutical company’s stock worth $5,952,333,000 after buying an additional 1,471,980 shares during the last quarter. Norges Bank acquired a new position in Pfizer during the fourth quarter worth $3,351,891,000. Nuveen Asset Management LLC boosted its stake in Pfizer by 18.0% during the fourth quarter. Nuveen Asset Management LLC now owns 28,086,667 shares of the biopharmaceutical company’s stock worth $1,658,518,000 after buying an additional 4,278,167 shares during the last quarter. Finally, Swiss National Bank boosted its stake in Pfizer by 14.1% during the first quarter. Swiss National Bank now owns 24,310,941 shares of the biopharmaceutical company’s stock worth $1,258,577,000 after buying an additional 3,000,100 shares during the last quarter. 66.50% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, SVP Jennifer B. Damico sold 4,218 shares of the stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $53.96, for a total value of $227,603.28. Following the transaction, the senior vice president now owns 10,846 shares in the company, valued at approximately $585,250.16. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.05% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on PFE. Berenberg Bank set a $50.00 price objective on Pfizer in a research note on Friday, May 27th. JPMorgan Chase & Co. set a $57.00 price target on Pfizer in a research note on Tuesday, June 28th. Morgan Stanley decreased their price target on Pfizer from $52.00 to $49.00 and set an “equal weight” rating on the stock in a research note on Friday, July 8th. SVB Leerink decreased their price target on Pfizer from $55.00 to $53.00 and set a “market perform” rating on the stock in a research note on Friday, July 29th. Finally, Wells Fargo & Company decreased their price target on Pfizer from $60.00 to $55.00 in a research note on Wednesday, May 4th. Nine equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Pfizer Price Performance

Shares of NYSE PFE opened at $49.86 on Wednesday. The stock’s 50-day moving average is $50.59 and its two-hundred day moving average is $50.92. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.42 and a quick ratio of 1.20. Pfizer Inc. has a 1-year low of $40.94 and a 1-year high of $61.71. The company has a market cap of $279.83 billion, a price-to-earnings ratio of 9.76, a price-to-earnings-growth ratio of 0.61 and a beta of 0.67.

Pfizer (NYSE:PFEGet Rating) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.95 by $0.09. Pfizer had a return on equity of 43.18% and a net margin of 28.92%. The company had revenue of $27.74 billion for the quarter, compared to the consensus estimate of $26.20 billion. During the same quarter in the prior year, the business earned $1.07 EPS. Pfizer’s revenue was up 46.8% on a year-over-year basis. Analysts forecast that Pfizer Inc. will post 6.54 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Wednesday, June 29th will be issued a dividend of $0.40 per share. The ex-dividend date is Thursday, July 28th. This represents a $1.60 annualized dividend and a yield of 3.21%. Pfizer’s dividend payout ratio (DPR) is 31.31%.

Pfizer Company Profile

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Further Reading

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.